All In Biotech

Drug Trial Radar · NCT04008186

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Jun 14, 2019

Primary completion

Aug 18, 2019

Study completion Aug 28, 2019

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Covance
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.

Conditions

  • Healthy Adult Subjects

Interventions

  • OmaveloxoloneDrug

    50 mg capsules

  • Midazolam oral solutionDrug

    2 mg/mL oral solution

  • Repaglinide 1 MGDrug

    1 mg tablet

  • MetFORMIN 500 Mg Oral TabletDrug

    500 mg tablet

  • RosuvastatinDrug

    10 mg tablet

  • Digoxin tabletDrug

    0.25 mg tablet

  • Gemfibrozil TabletsDrug

    600 mg tablet

  • Itraconazole capsuleDrug

    100 mg capsule

  • Verapamil PillDrug

    120 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Maximum concentration (Cmax) of probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)Time frame: 28 days
  2. Part 1 - Area under the plasma concentration-time curve of (AUC) for probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)Time frame: 28 days
  3. Part 2 - Maximum concentration (Cmax) of omaveloxoloneTime frame: 23 days
  4. Part 2 - Area under the omaveloxolone concentration-time curve (AUC)Time frame: 23 days
  5. Part 3 - Maximum concentration (Cmax) of omaveloxoloneTime frame: 23 days
  6. Part 3 - Area under the omaveloxolone concentration-time curve (AUC)Time frame: 28 days
  7. Part 4 - Maximum concentration (Cmax) of omaveloxoloneTime frame: 23 days
  8. Part 4 - Area under the omaveloxolone concentration-time curve (AUC)Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit (CRU) Inc.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.